Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is making progress in the clinical development of its lead multiple sclerosis (MS) therapy candidate, LUCID-MS, following the completion of Phase 1 studies in healthy volunteers. The company reported that the therapy demonstrated a favorable safety profile and was generally well tolerated, supporting its advancement into patient-focused studies. In April 2026, Quantum BioPharma submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for LUCID-MS, paving the way for a planned Phase 2 clinical trial in people living with multiple sclerosis.
LUCID-MS is designed to target demyelination and protect or restore myelin integrity, addressing the underlying neurodegenerative mechanisms of MS. The company believes the therapy may offer a differentiated, potentially first-in-class approach because it aims to directly address myelin loss and neurodegeneration, rather than relying solely on immune modulation. To support the program's advancement, Quantum BioPharma is planning a partnership with Allucent and engaging neurological specialists to strengthen operational support.
The full article detailing these developments is available at https://ibn.fm/AUhNl. Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is focused on the research and development of Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models.
In addition to its MS program, Quantum BioPharma has developed unbuzzd, an over-the-counter product for alcohol misuse, and spun out its OTC version to Unbuzzd Wellness Inc. (UWI). Quantum retains a 19.84% ownership stake in UWI as of March 31, 2026, and is entitled to royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. The company retains full rights to develop similar products for pharmaceutical and medical uses.
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM. Forward-looking statements in this article involve risks and uncertainties, including those detailed in the company's filings with the SEC, and the company undertakes no duty to update this information unless required by law.
